NeoVac

NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics.

Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of administration, and improved safety profiles.

Applications span infectious disease vaccines, oncology, and broader RNA medicine programmes. NeoVac has advanced a Phase I mRNA vaccine candidate in UK volunteers.